FTSE MIB
33.807,37 +60,71 (+0,18%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
79,79 +0,79 (+1,00%) Bitcoin EUR
53.949,92 +398,76 (+0,74%)
Alvotech (ALVO)
| Chiusura precedente | 14,50 |
| Aperto | 14,53 |
| Denaro | 14,46 x 200 |
| Lettera | 14,52 x 100 |
| Min-Max giorno | 14,37 - 14,56 |
| Intervallo di 52 settimane | 6,70 - 18,00 |
| Volume | |
| Media Volume | 272.077 |
| Capitalizzazione | 4,048B |
| Beta (5 anni mensile) | 0,07 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,43 |
| Prossima data utili | 21 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,50 |
GlobeNewswireAlvotech Provides Update on Status of U.S. Biologics License Application for AVT04
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT04, a biosimilar candidate to Stelara® (ustekinumab). As expected, the CRL noted that certain deficiencies, which were conveyed following the FDA’s inspection of the company’s Reykjavik fac
- GlobeNewswire
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price. Islandsbanki will post bids and offers on the exchange amounting to at least ISK 8 million at market value at any given time at a price determined by Islandsbanki, wh
- GlobeNewswire
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company, today announced that they have entered into an exclusive licensing agreement for AVT23 (also called ADL018), a proposed biosimilar to Xolair® (omalizumab), which is currently in clinical developm
